ISO 9001:2015 Genetracer Biotech GENETRACER BIOTECH; Genomic diagnostic laboratory has implemented and maintains a Quality Management System which fulfills the requirements of the following standard ISO 9001:2015 - Genetic evaluation of tumors from blood samples (liquid biopsy) for studies of the genetic profile of cancerous lesions [...]
Genetracer Biotech participates in the National Symposium of Applied Genomics in Oncology 2018 on March 20, 2018 as sponsor. URL: Enter PDF: Download
On October 19th will be held the Ion world tour, in which Genetracer Biotech will act as a speaker talking about the liquid biopsy in cancer diagnosis: ctDNA vs FFPE in colorectal cancer.
Genetracer Biotech will be present from September 26 to 29 at the Brazilian Congress of Clinical Pathology, offering a session of the use of the liquid biopsy in the oncological diagnosis by Dr. Patricia Ruiz-Ontañon.
Genetracer Biotech has obtained the certificate of excellence from the European Commission rating the project proposal as high quality in a highly competitive evaluation process.
The Liquid Biopsy has been ranked among the top 10 emerging technologies in 2017 by the World Economic Forum panel of experts.
On June 16, 2017 Genetracer Biotech received the "Cantábrico Excelente" Award 2017 in the category of Sanitary Technology. Read more
Genetracer Biotech will be present, Between the days 19 and 22 of June, in the BIO INTERNATIONAL CONVENTION 2017 which is held in San Diego. Through the following link you can see our location.
Genetracer Biotech participated in 2016 in the European Molecular Genetics Quality Network (EMQN) whith two external quality assessment schemes: NextGen DNA Sequencing (vGermline) NextGen DNA Sequencing (vSomatic) Both of them where passed with satisfactory result.
Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
Genetracer Biotech will utilize Fluxion's IsoFlux circulating tumor cell (CTC) system to provide NGS-based liquid biopsy services for lung and colon cancers. More information